Edging toward a pivotal readout, Biogen picks a new discovery partner for ophthalmic gene therapy
Almost two years after Biogen swooped again into the ophthalmic gene therapy field with an $800 million buyout of eye-focused Nightstar Therapeutics, it’s turning to a young player for a new program.
Germany’s ViGeneron will be deploying its next-generation AAV vectors to generate candidates for a target — Biogen isn’t disclosing which exactly — that would treat inherited eye disease. The big biotech partner has another target in mind, for which it has the option to add within two years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.